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Studies have shown that hepatitis C virus (HCV)-infected alcoholics have more severe biochemical and 
histological evidence of liver disease than anti-HCV-negative patients. One possible mechanism for the 
increased liver damage is that alcohol may have a stimulatory effect on HCV replication. This study was 
therefore carried out to investigate the seroprevalence of HCV virus among alcoholics. Two-hundred 
and seventy (270) alcoholics and fifty (50) control subjects at selected locations in Jos South local 
government area (LGA), of Plateau State were screened for HCV antibodies using grand rapid 
diagnostic test strip. Structured questionnaire was employed to obtain demographic data of study 
subjects. Overall, the prevalence of HCV infection was found to be 45(16.7%) in response to alcoholics 
while the non-alcoholic (control) subjects recorded 3 (6.0%) positivity, [(x2 = 3.765); P > 0.05]. Gender 
consideration showed that females subjects had a higher prevalence of 25 (9.3%) compared to males 
with 20 (7.4%) among the alcoholic subjects. The 19 – 30 years age group recorded the highest 
seroprevalence of 14 (5.2%) to the HCV, [(x2 = 4.757); P > 0.05], while no significant difference was 
observed among positive subjects screened for serum aminotranferase levels in relation to age and 
gender. Available evidence from this study indicates that alcoholic consumption is a strong 
determinant of HCV infection. Drastic measures at creating awareness and the need for routine 
screening among alcoholics should be given due consideration. However, future HCV studies need to 
quantify concurrent alcoholic consumption to further our understanding of the total burden of illness 
from alcohol associated HCV in the community. 
 





The hepatitis C virus (HCV) is a small (50 nm in size) 
enveloped, single-stranded, positive sense RNA virus in 
the family Flaviviridae. HCV mainly replicates within 
hepatocytes in the liver. HCV virus is a blood-borne, 
infectious viral disease (Ryan and Ray, 2004). The infec-
tion can cause liver inflammation that is often asymp-
tomatic, but ensuing chronic hepatitis can result later in 
cirrhosis (fibrotic scarring of the liver) and liver cancer. 
Studies have shown that HCV accounts for between 75 
to 95% post transfusion hepatitis (Zuckerman and 
Thomas, 1993). Approximately, 170 million people world 
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Abbreviations: HCV, Hepatitis C virus; HCC, hepatocellular 
carcinoma. 
Prevalence of HCV is considerably higher in developing 
countries; it reaches about 4 to 6% in selected population 
in parts of African and Middle East (Campbell et al., 
2005). Almost one–third of alcoholics with clinical 
symptoms of liver disease have been infected with HCV 
which is four times the rate of HCV infection found in 
alcoholics who do not have liver disease (Coelho–Little et 
al., 1995; Mendenhall et al., 1991; Takase et al., 1993).  
HCV is transmitted primarily through contaminated 
blood and less effectively through human bodily secre-
tions. HCV has been detected in saliva, urine, semen and 
ascetic fluid (Campbell et al., 2006). People with HCV 
infection often experience mild symptoms and cones-
quently does not seek treatment (Ryan et al., 2004).  
Patients infected with HCV, have an 80 - 85% chances 
that the infection will persist, hence progressing to chro-
nic HCV infection with multiple manifestation. The most 
common is progressive liver disease associated with 





cirrhosis (Mann’s, 2001). Several factors may accelerate 
the progression of hepatitis C, including older age at the 
time of infection and excessive alcohol consumption 
(Poynard et al., 2001). 
The diagnosis of hepatitis C is rarely made during the 
acute phase of the disease because the majority of 
people infected experience no symptoms during this 
phase of the disease. Those who experience acute 
phase symptoms are rarely ill enough to seek medical 
attention. The diagnosis of chronic phase hepatitis C is 
also challenging due to the absence or lack of specificity 
of symptoms until advanced liver disease develops, 
which may not occur until decades into the disease 
(Johnson et al., 1993). Hepatitis C testing begins with 
serological blood tests used to detect antibodies to HCV. 
Anti-HCV antibodies can be detected in 80% of patients 
within 15 weeks after exposure, in > 90% within 5 months 
after exposure and in > 97% by 6 months after exposure. 
Overall, HCV antibody tests have a strong positive 
predictive value for exposure to the hepatitis C virus, but 
may miss patients who have not yet developed 
antibodies (seroconversion), or have an insufficient level 
of antibodies to be detectable (Zignego et al., 2006). 
Starting HCV therapy early in the disease stage may 
present a better opportunity to achieve undetectable HCV 
viral load or a sustained virological response. Response 
to HCV treatment may be better in early disease, due in 
part to perhaps less mutations and damage to the liver 
having occurred and because the person's immune 
system may be able to be more responsive to the virus 
and to treatment. Heavy alcohol use can be detrimental 
to HCV–infected patients’ long–term response to 
interferon therapy. It is likely that alcohol affects HCV 
treatment effectiveness both because drinking tends to 
interfere with patients’ adherence to therapy and because 
alcohol interferes with interferon therapy’s antiviral 
actions (Watanabe et al., 2003; Scott et al., 2006). There 
is no vaccine against HCV, majorly due to the high 
mutability of the HCV genome which enables it escapes 
detection by the antibodies, and this mutating ability of 
the virus makes vaccine development difficult. Lack of 
knowledge of any protective immune response following 
HCV infection also impedes vaccine research. In the 
absence of a vaccine, all precautions to prevent infection 
must be taken. 
This study was embarked upon to determine the 
prevalence of HCV antibody among   alcoholic subjects 
at selected locations in Jos South local government area 
(LGA) of Plateau State. The study is also aimed to further 
create awareness to the public and other health care 








This cross-sectional study was conducted in  Vwang  community  in 




Jos South local government area of Plateau State. The choice of 
this area is based on the life style of which includes high alcohol 





The Vwang community is approached through the village ‘head’ 
who later informed his subjects to participate in the study.  Only 






The questionnaire administered to the subjects was designed to 
collect socio– demographic information about the participants and 
factors that might predispose them to the infectious agents. All the 
subjects screened completed an informed consent form.  
 
 
Sample collection  
 
From all the patients that completed the questionnaire, 3 ml of 
blood was collected from each patient via venous puncture 
technique using sterile syringe after swabbing the area with 70% 
alcohol. The serum was separated by centrifugation into a cryovial 





The HCV one step hepatitis C virus test strip is a rapid 
chromatographic immunoassay for the qualitative detection of 
antibody to hepatitis C virus in serum or plasma. The test strip is a 
qualitative, membrane based immunoassay for the detection of 
antibody to HCV in serum or plasma. The membrane is coated with 
recombinant HCV antigen on the test line region of the strip. When 
testing the serum or plasma specimen reacts with the protein 
coated particles. The mixture migrates upward on the membrane 
chromatographically by capillary action to react with recombinant 
HCV antigen on the membrane and generate a colored line. The 
presence of this colored line indicates a positive result, while its 










Table 1 shows the distribution of HCV among alcoholics 
and non alcoholic subjects. Highest prevalence of 45 
(16.7%) was recorded out of a total of 270 alcoholics 
screened, while 3 (6.0%) was recorded among the non 
alcoholic (control) subjects screened. 
From Table 2, the highest prevalence of 14 (5.2%) was 
recorded among subjects aged 19 - 30 years, while the 
lowest prevalence of 4 (1.5%) was recorded among those 
aged 51 – 60 years. Table 3 shows the prevalence of 
HCV in relation to gender. Highest prevalence of HCV in 
alcoholics was obtained among the female subjects with 
25 (9.3%) while male subjects recorded 20 (7.4%). 




Table 1. Overall distribution of HCV infection amongst subjects (alcoholics and non-alcoholics) screened. 
 






Alcoholics  270 (84.4%) 45 (14.1%) 225 (70.3%) 
Non alcoholics (control group)  50 (15.6%) 3 (0.90%) 47 (14.7%) 
Total 320 (100.0%) 48 (15.00%) 272 (85.00%) 
             




Table 2. Age distribution of HCV infection amongst (alcoholics) subjects screened. 
 
Age range Total No. of 
subjects screened 
Total No. of 
positive subjects 
Total No. of 
negative subjects 
19 - 30 120 14 (7.2%) 106 (32.1%) 
31 - 40 71 12(5.2%) 59 (22.6%) 
41 - 50 50 10 (3.2%) 40 (16.7%) 
51 - 60 15 4 (0.6%) 11 (6.8%) 
61 - 70 14 5 (0.3%) 9 (1.6%) 
Total 270 45 (16.7%) 225 (83.3%) 
 




Table 3. Distribution of HCV prevalence based on gender amongst (alcoholics) subjects screened. 
 
Gender No. of subjects screened No. of Positive subjects No. of Negative subjects 
Males 114 20 (7.4%) 139 (51.5%) 
Females 111 25 (9.3%) 131 (48.5%) 
Total 225 45 (16.7%) 270 (100.0%) 
 




Table 4. Risk factors based on clinical history of (alcoholic) subjects screened. 
 
Risk factors Total No. of subjects Total No. positive Total No. negative 
History of transfusion with blood  50 4 (1.5%) 46 (17.0%0 
History of Surgical operation 30 2 (0.7%) 28 (10.4%) 
Total 80 (29.6%) 6 (2.2%) 74 (27.4%) 
 




Risk factors put into consideration showed that subjects 
with history of blood transfusion recorded 4 (1.5%) 
prevalence out of the 50 responses obtained in that 
regard. X2 analysis indicated no significant difference 
between transfused subjects and those not transfused 
[with P value of 0.826 that is, (P > 0.05)], similarly risk 
factors based on subjects with history of surgery showed 
a record of 2 (0.7%) prevalence out of the 30 alcoholic 
subjects considered (Table 4). 
The serum aminotransferase level recorded was based 
on the 45 (16.7%) HCV positive subjects. Of these, 29 
(10.7%) showed a slight elevation of liver enzyme 
(transaminases), while 16 (5.9%) recorded normal 
enzyme level, out of which, subjects aged 19 - 30 years 
recorded 9 (3.3%) while those aged 51 - 60 had 3 (1.1%) 
with elevated enzyme level as evidenced in Table 5. 
The serum aminotransferase level recorded among the 
male positive subjects showed an elevation of liver 
enzyme among 14 (5.2%) subjects, compared to female 
subjects with 17 (6.3%) that recorded an abnormal 





HCV is one of the major causes of  chronic  liver  disease 




Table 5. Determination of serum transaminase level (%) on positive subjects in relation 
to age distribution. 
 
Age Total non of subjects Total No. abnormal Total No. normal 
19 - 30 14 9 (3.3%) 5 (1.9%) 
31 - 40 12 8 (2.9%) 4 (1.5%) 
41 - 50 10 6 (2.2%) 4 (1.5%) 
51 - 60 4 3 (1.1%) 1 (0.4%) 
61 - 70 5 3 (1.1%) 2 (0.7%) 
Total 45 29 (10.7%) 16 (5.9%) 
 




 Table 6. Determination of serum transaminase level on positive subjects in relation to 
gender distribution. 
 
Gender Total No. subject Total No. abnormal Total No. normal 
Males 20 14 (5.2%) 9 (3.3%) 
Females 25 17 (6.3%) 8 (2.9%) 
Total 45 31 (11.5%) 17 (6.2%) 
 




and hepatocellular carcinoma (HCC) worldwide 
(Campbell et al., 2006). Numerous risk factors contribute 
to HCV acquisition and multiple risk factors may be 
present in a single individual. In the present study, anti- 
HCV antibodies were detected in 16.7% among 
alcoholics. However, a very similar prevalence (16.0%) 
was found in a recent review of published data involving 
799 unselected individuals with alcohol abuse, (Heintges 
and Wands, 1997). Previous studies conducted in Brazil 
also found anti- HCV antibodies in 12 to 16% of 
unselected alcoholic patients (Cavazzola et al., 1994). In 
contrast, serum markers of HCV infection were detected 
in up to 36% of Brazilian patients with alcoholic cirrhosis 
(Strauss et al, 1992). In a similar work done by Robert et 
al. (2003), a prevalence of 2 - 14% was reported. This 
figure obtained in this study is therefore alarming and 
calls for concern. 
The 19 – 30 years age group recorded the highest 
infection rate in the communities studied. This is in 
agreement with the work of Amina et al. (2004) who 
stated that subjects with 20 - 24 years mean age group 
had the highest HCV transmission prevalence rate. One 
could argue that the average age of the positive subjects 
in this study is relatively high, since younger people are 
more predisposed to several social lifestyles. 
Females are more infected than males in this study.
 The rate of infection among these subjects based 
on gender as shown on Table 3 shows a P-Value of 
0.391 which also shows no significant difference; this 
however does not correspond with previous result which 
said that men have HCV infection than women (Poynard 
et al., 2001). However, from this research work, women 
have the highest prevalence, which may due to the fact 
that women in these localities consume the local brew as 
stimulants before embarking on their activities on the 
farm. Other factors like manicuring, sharing of sharp 
objects like razor and nail files, could be other possible 
predisposing factors. 
Risk factors put into consideration showed that subjects 
with history of blood transfusion recorded 4(1.5%) pre-
valence out of the 50 responses obtained in that regard. 
X2 analysis indicated no significant difference between 
transfused subjects and those not transfused [with P 
value of 0.826 that is, (P > 0.05)]. This result agrees with 
the research done by Alter (1999), where he found that  
HCV infection can easily be trans-mitted through blood 
transfusion and that surgical operation can be a 
predisposed fact when equipment used are not probably 
sterilized. With these alarming facts and estimates, there 
are needs for routine screening to enable early diagnosis 
and treatment of the virus and to further prevent 





Excessive alcohol consumption among patients infected 
with chronic hepatitis C is likely to result in more severe 
liver injury, promoting cirrhosis and increasing the risk for 
development of liver cancer (specifically, hepatocellular 
carcinoma). Although the mechanisms by which chronic 
hepatitis C progresses to more severe liver disease in 
alcoholic patients have not been clearly established. 
They may include an alcohol–induced increase in viral 
replication, rapid mutation of HCV leading to greater viral 
complexity, increased liver–cell  death  and  inflammatory 




response, suppression of immune responses, accumu-
lation of fat in the liver and accumulation of excess iron in 
body tissues.  Due to the unavailability of vaccine for 
HCV infection at the moment coupled with the cost effect 
of such drugs, a preventive measures should be vigo-
rously pursued as part of public awareness.     
The basic means of preventing HCV transmission is by 
ensuring that infectious materials from infected persons 
or carriers are kept safe from getting in contact with 
persons susceptible to HCV infection. Adequate precau-
tion should be taken when handling people known or 
presumed to be infected since their blood and body fluid 
can establish a state of infection. Promotion of behaviou-
ral changes among the general public should be 
encouraged. Health care workers are urged to ensure 
safe injection practices. Risk reduction counseling is 
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